Form D · Biotechnology
Ember Therapeutics, Inc.
Boston, MA · CIK 0001537900
Offering snapshot reported Dec 21, 2011 · SEC filing
- Reported sold
- $3.19M Offering amount: $34.2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 12, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 21, 2011 | Initial | $3,190,608 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-170448
Source: Form D, filed Dec 21, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mitchell Bloom | Executive |
| Kevin Gillis | Executive |
| Dan Lynch | Director |
| Bruce Spiegelman | Director |
| Louis Tartaglia | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
29 Newbury St Floor 3
Boston, MA, 02116
Boston, MA, 02116